Health Condition 1: I110- Hypertensive heart disease with heart failure
Conditions
Interventions
None listed
Sponsors
Abbott Healthcare Pvt Ltd
Eligibility
Inclusion criteria
Inclusion criteria: 1 Male & female patients with Age > 18 years at baseline 2 Patients with a diagnosis of Heart Failure with Reduced Ejection Fraction(documented LVEF 3 Patients with current Class NYHA II or III 4 Patients of HFrEF being treated on an outpatient basis 5 Patients who will give consent for participation in the study
Exclusion criteria
Exclusion criteria: 1 Patients 2 Patients with Heart failure with mid-range EF (HFmrEF)(LVEF40-49%) and Heart failure with preserved EF (HFpEF)(LVEF=50%) 3 Patients of Heart failure who are currently admitted in the hospital 4 Patients with planned or history of heart transplant, Left ventricular assist device (LVAD) or dialysis 5 Patients with clinically significant condition which in the opinion of the Investigator makes him/her unfit to participate in the study 6 Patients with Major recurrent life-threatening cardiac arrhythmia 7 Patients with Atrial Fibrillation 8 Patients with implantable cardiac device like pace maker and defibrillator 9 Patients with history of terminal renal/hepatic/pulmonary disease 10 Patients as a part of any other clinical study on an Investigational Product.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Average resting HR in patients with HFrEF, on treatmentTimepoint: At baseline and at EOS | — |
Secondary
| Measure | Time frame |
|---|---|
| 1)Average blood pressure in patients with HFrEF, on treatmentTimepoint: At baseline and at EOS;2) Prescription pattern of HR lowering medications – Beta blockers, Ivabradine, Digoxin and Calcium channel blockers (Non-DHPs)Timepoint: At baseline and at EOS;a) Number of patients on Beta blockers or Ivabradine or Digoxin or Calcium channel blockers (Non-DHPs)Timepoint: At baseline and at EOS;b. Number of patients on co-administration/ combination of different class of HR lowering medications (Beta blockers/ Ivabradine/ Calcium channel blockers (Non-DHPs)/ Digoxin)Timepoint: At baseline and at EOS;c. Number of patients undergoing change in ( addition/ deletion of class of drug, change of drug within the same class) heart rate lowering medicationTimepoint: At baseline and at EOS;3) Number of Patients having comorbid conditions like DM/HTN/Dyslipidemia.Timepoint: At baseline and at EOS | — |
Countries
India
Contacts
Public ContactDr Shivani Acharya
Abbott Healthcare Private Limited
Outcome results
None listed